Osteoarthritis: Osteoporotic OA: a reasonable target for bone-acting agents.
Where this comes from
- Record sourced from PubMed, PMID 23857129.
- Also identified by DOI 10.1038/nrrheum.2013.113.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Beneficial effects of bone-acting drugs in osteoarthritis (OA) are increasingly reported, but reliable conclusions regarding their efficacy are hindered by methodological drawbacks in study design. Identifying patients with osteoporotic OA, a phenotype defined by decreased density associated with high remodelling in subchondral bone, might improve the success of bone-directed agents.
Medical subject headings
- Bone Density Conservation Agents
- Diphosphonates
- Osteoarthritis, Knee
- Osteoporosis